Evaluation of Interprofessional Relations Between Primary Care and Hospital Centers in the Experimentation of Medical Cannabis in France Carried Out by the ANSM (ECIPCanna) (ECIPCanna)

September 12, 2024 updated by: University Hospital, Brest

Evaluation of Interprofessional Relations Between Primary Care and Hospital Centers in the Experimentation of Medical Cannabis in France Carried Out by the ANSM

An observational study to explore inter-professional relations and perceptions around the experimentation of medical cannabis, conducted by the French National Agency for Safety and Health. The study aims to identify the barriers and facilitators to prescribing and dispensing medical cannabis and to analyse healthcare professionals' perceptions of medical cannabis in France. Using a qualitative method based on semi-directed interviews and focus groups, the study will involve hospital physicians, general practitioners, and community and hospital pharmacists participating in the the French National Agency for Safety and Health experiment. The primary objective is to understand the dynamics between health professionals involved in the medical cannabis programme, while secondary objectives include proposing strategies to overcome barriers to the provision of medical cannabis.

Study Overview

Status

Enrolling by invitation

Conditions

Study Type

Observational

Enrollment (Estimated)

108

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Brest, France, 29609
        • CHU Brest

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Healthcare professionals participating in the experiment conducted by the French National Agency for Safety and Health:

  • Hospital doctors
  • General practitioners
  • Community pharmacists
  • Hospital pharmacists

Description

Inclusion Criteria:

  • Healthcare professional participating in the experiment conducted by the the French National Agency for Safety and Health: Hospital doctor, general practitioner, community pharmacist, or hospital pharmacist
  • Non-opposition

Exclusion Criteria:

  • Refusal of participation by hospital doctor, general practitioner, community pharmacist, or hospital pharmacist

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Exploring the inter-professional relationships of those involved in the medical cannabis experiment being conducted by the French National Agency for Safety and Health
Time Frame: 1 day
Construct mental maps of representations relating to the prescription and dispensing of medical cannabis.
1 day

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Brest

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

October 1, 2024

Primary Completion (Estimated)

December 31, 2025

Study Completion (Estimated)

December 31, 2026

Study Registration Dates

First Submitted

April 4, 2024

First Submitted That Met QC Criteria

September 12, 2024

First Posted (Estimated)

September 19, 2024

Study Record Updates

Last Update Posted (Estimated)

September 19, 2024

Last Update Submitted That Met QC Criteria

September 12, 2024

Last Verified

September 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 29BRC23.0215

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

All collected data that underlie results in a publication

IPD Sharing Time Frame

Data will be available beginning three years and ending fifteen years following the final study report completion

IPD Sharing Access Criteria

Data access requests will be reviewed by the internal committee of Brest UH. Requestors will be required to sign and complete a data access agreement

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Medical Cannabis

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Suriname

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe